

## **StatFinn and EPID Research join forces in clinical data analytics and Real-World Evidence**

(Espoo, Finland, 16.1.2017) StatFinn and EPID Research have decided to merge their operations in order to offer a full range of services to their clients in clinical data analytics and Real-World Evidence from Phase I to Phase IV and beyond. The combined company employs over 70 experts with presence in five countries: Estonia, Finland, Poland, Sweden and Switzerland. The new combination will carry on using both brands StatFinn and EPID Research.

StatFinn is a prominent force and expert in clinical trial data management and biostatistics. It has shown profitable organic growth since it was founded in 2005. EPID Research is an expert in Real-World Evidence and epidemiology. It was established in 2010 and has turned in profitable organic growth every financial year. The merger will be done with a share swap where EPID Research will become as a fully owned subsidiary of StatFinn. The new combination will carry on using both brands StatFinn and EPID Research.

“I’m enthusiastic about this merger. It gives us new opportunities to expand our service offering by combining clinical data analytics with Real-World Evidence. With this merger, we are in a better position to explore new growth areas in fast growing digital health business”, says Pasi Korhonen, the founder of both companies, CEO of StatFinn and Research Director of EPID Research.

The merger will create a combination of two well-established growth companies. The combined company will employ over 70 experts and continues to maintain over 20 percent annual business growth with strong synergies in sales and operations. Both companies have long-term trusted relationships with big pharma clients. Together they will have a full range of services in clinical trial biostatistics and data management, epidemiology and Real-World Evidence that covers the life cycle of an individual pharmaceutical from Phase I to Phase IV and beyond. The merged company has presence in five countries: Estonia, Finland, Poland, Sweden and Switzerland.

“This merger further fuels our global expansion, while producing clear benefits to our clients, partners and personnel,” says Eero Mertano, CEO and founder of EPID Research.

Eero Mertano will be nominated as the CEO of the merged company while he continues to lead the business of EPID Research. Pasi Korhonen continues to lead the business of StatFinn as Chief Scientific Officer and assumes the Chairman of the Board position from Mika Mustonen who continues as a member of the Board with Jouko Marttila. The senior management is further strengthened by a recruitment of a new Chief Financial Officer, Tuomas Wegelius, who has vast global experience in financial and human resource management.

“Business continues as usual with focus on projects, clients and personnel. We will first capitalize on synergies in the financial and administrative processes as well as sales. Further operative integration will happen gradually during 2017”, explains Pasi Korhonen.

The board, existing management and shareholders of both companies have given their consent to the merger, and the official closings will take place in the next few months.

*For additional information:*

**Pasi Korhonen**, CEO, StatFinn, [pasi.korhonen@statfinn.fi](mailto:pasi.korhonen@statfinn.fi), +358 50 365 2990

**Eero Mertano**, CEO, EPID Research, [eero.mertano@epidresearch.com](mailto:eero.mertano@epidresearch.com), +358 40 769 6275